Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism

Q2/H1 2023 Financial Results

August 17, 2023

2:00pm CET (8:00am ET)

Read more


Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)

Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions

Our research

Applying our peptide platform to specialty disease areas to invent novel therapies.
Read more

Late-stage pipeline

Advancing fully owned development programs with Phase 3 in two rare disease programs. See our pipeline

About Zealand

Get a brief overview on Zealand and learn more about our company. Read more


Information for analysts, investors, and shareholders.
Read more